Exelixis (Exelixis) Days Sales Outstanding

: 46.18 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Exelixis's average Accounts Receivable for the three months ended in Dec. 2023 was $243 Mil. Exelixis's Revenue for the three months ended in Dec. 2023 was $480 Mil. Hence, Exelixis's Days Sales Outstanding for the three months ended in Dec. 2023 was 46.18.

The historical rank and industry rank for Exelixis's Days Sales Outstanding or its related term are showing as below:

EXEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.49 Med: 51.53 Max: 64.12
Current: 46.55

During the past 13 years, Exelixis's highest Days Sales Outstanding was 64.12. The lowest was 43.49. And the median was 51.53.

EXEL's Days Sales Outstanding is ranked better than
72.3% of 888 companies
in the Biotechnology industry
Industry Median: 72.335 vs EXEL: 46.55

Exelixis's Days Sales Outstanding declined from Dec. 2022 (46.26) to Dec. 2023 (46.18).

Exelixis Days Sales Outstanding Historical Data

The historical data trend for Exelixis's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

53.15

51.74

56.41

56.35

45.09

Exelixis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																46.26	50.08	45.32	46.50	46.18

Competitive Comparison

For the Biotechnology subindustry, Exelixis's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exelixis Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Exelixis's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Exelixis's Days Sales Outstanding falls into.

Exelixis Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Exelixis's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (214.784	+	237.407)	/	2 )	/	1830.208	*	365
=	226.0955					/	1830.208	*	365
=	45.09

Exelixis's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (248.113	+	237.407)	/	2 )	/	479.652	*	365 / 4
=	242.76					/	479.652	*	365 / 4
=	46.18

Exelixis (NAS:EXEL) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Exelixis Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Exelixis's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis (Exelixis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

EX9:Germany EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Executives

Patrick J. Haley	officer: Sr. Vice President, Commercial	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel	officer: EVP and General Counsel	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson	director	590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab	officer: CSO/EVP Disc & Trans Research	EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson	officer: EVP Prod Dev & Med Aff & CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner	officer: EVP and CFO	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp	director, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski	director	SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber	director	3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum	director	C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb	officer: EVP, Discovery Research & CSO	PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste	director	515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey	director	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083